Key statistics
As of last trade Belite Bio Inc (BLTE:NAQ) traded at 178.01, -11.00% below its 52-week high of 200.00, set on Feb 03, 2026.
52-week range
| Open | 176.61 |
|---|---|
| High | 179.00 |
| Low | 171.78 |
| Bid | 175.50 |
| Offer | 178.95 |
| Previous close | 175.26 |
| Average volume | 167.71k |
|---|---|
| Shares outstanding | 37.51m |
| Free float | 34.41m |
| P/E (TTM) | -- |
| Market cap | 6.57bn USD |
| EPS (TTM) | -1.55 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 19:05 GMT.
More ▼
Announcements
- Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
- Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
- Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
- Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
- New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
- Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
- Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
- Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
- Belite Bio to Participate in the 2025 Maxim Growth Summit
More ▼
